ANDA 205600, held by Micro Labs Ltd India. Levofloxacin.
As of Nov 16, 2026, ANDA 205600 (Levofloxacin), held by Micro Labs Ltd India, was first approved by FDA on Feb 27, 2019, with 1 approved supplement and 0 published complete response letters.
Levofloxacin ophthalmic solution is indicated for the treatment of corneal ulcer caused by susceptible strains of the following bacteria: Gram-positive bacteria: Corynebacterium species Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumonia Viridans group streptococci* Gram-negative bacteria: Pseudomonas aeruginosa Serratia marcescens* *Efficacy for this organism was studied in fewer than 10 infections
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 27, 2019 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Levofloxacin1.5% · solution/drops;ophthalmic | Levofloxacin | Discontinued |
| Aug 11, 2023 | Supplement 1Labeling · Standard review | Approved | None posted |
| Feb 27, 2019 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters